Therapy for chemotherapy-induced peripheral neuropathy

JAMA

Volumn 310, Issue 5, 2013, Pages 537-538

  Seretny, Marta ^a   Colvin, Lesley ^a   Fallon, Marie ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DULOXETINE; PLACEBO;

CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EFFECT SIZE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LETTER; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PARALLEL DESIGN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT INDICATION;

EID: 84881257938     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.7902     Document Type: Letter

References (5)

1. Smith EM, Pang H, Cirrincione C, et al; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359-1367.
2. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain. 2010;149(2):177-193.
3. Eippert F, Bingel U, Schoell ED, et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron. 2009;63(4):533-543.
4. Quessy SN, Rowbotham MC. Placebo response in neuropathic pain trials. Pain. 2008;138(3):479-483.
5. Bingel U, Wanigasekera V, Wiech K, et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med. 2011;3(70):70ra14.